Ube, Japan

Kasumi Sudoh

This inventor holds 1 USPTO granted patent. Top assignee: Ube Industries, Inc.. Active years: 1992.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 1992

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Journey of Inventor Kasumi Sudoh

Introduction: Kasumi Sudoh, a dedicated inventor from Ube, Japan, has made significant strides in the field of biotechnology. With a strong focus on monoclonal antibodies, Sudoh's work is marked by a commitment to developing innovative solutions for complex challenges.

Latest Patents: Sudoh holds a patent for a monoclonal antibody that specifically binds okadaic acids. This patent not only outlines the antibody itself but also details the process for producing it by culturing a cell strain capable of generating the antibody. The enzyme-labeled monoclonal antibody is instrumental for assaying okadaic acids, making it a valuable tool in both research and clinical settings.

Career Highlights: Throughout her career, Kasumi Sudoh has been recognized for her exceptional contributions to her field. Working at Ube Industries, Inc., she has focused her expertise on advancing the understanding and application of monoclonal antibodies. Her innovative approaches have helped to establish new methodologies in the detection and analysis of toxic compounds.

Collaborations: Sudoh has collaborated with notable colleagues such as Taizo Uda and Yukikatsu Itoh. Their collective expertise has fostered a collaborative environment that encourages the exchange of ideas and advancements in biotechnology.

Conclusion: Kasumi Sudoh exemplifies the spirit of innovation in the scientific community. Through her groundbreaking patent and collaborative efforts, she continues to push the boundaries of what is possible in the realm of monoclonal antibodies, paving the way for future discoveries and advancements.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…